RxDoctor Payments Data

Julia Ansari, MD

Interventional Cardiology · Joplin, MONPI 1780846881

Payments from drug & device makers

$24,309in general payments, 2019–2025

Across 281 payments — averaging $86.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$11K
  • Medtronic$5K
  • Abbott$2K
  • Abiomed$2K
  • Penumbra, Inc.$861
  • Biosense Webster, Inc.$749
  • plus $3K from 30 others

What the payments were for

  • Speaking & faculty fees$6,00025%
  • Grants$1451%
  • Travel & lodging$9,29038%
  • Food & beverage$8,86036%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,309 in reported general payments places this provider in the 65th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$107,059
Medicare patients
791
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol128$116,226
EliquisApixaban133$107,860
EntrestoSacubitril/Valsartan102$96,135
XareltoRivaroxaban43$45,032
BrilintaTicagrelor32$19,747
JardianceEmpagliflozin14$8,569
Ranolazine ErRanolazine66$4,528
Metoprolol Succinate253$3,717
Atorvastatin Calcium224$1,893
Diltiazem 24hr Er (Cd)Diltiazem Hcl79$1,561
Potassium Chloride73$1,284
ClopidogrelClopidogrel Bisulfate125$1,257
Spironolactone161$1,156
Digoxin48$1,103
Midodrine Hcl30$1,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$71$135,973160 claims
PfizerEliquis$227$107,860133 claims
NovartisEntresto$262$96,135102 claims
Johnson & JohnsonXarelto$207$45,03243 claims
Boehringer IngelheimJardiance$374$8,56914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →